Eli Lilly lifts 2019 profit forecast after third-quarter beat
Reuters
Published Oct 23, 2019 07:01AM ET
Eli Lilly lifts 2019 profit forecast after third-quarter beat
(Reuters) - Eli Lilly and Co (N:LLY) raised its 2019 profit forecast after reporting a better-than-expected quarterly profit on Wednesday, helped by performance of its diabetes drug, Humalog, and lower tax bill.
The drugmaker is one of the three main providers of insulin products and had agreed earlier this year to offer a half priced version of its insulin injection Humalog in response to intensifying pressure from politicians to lower drug costs for consumers.
Sales from both versions of the insulin injection fell 2.4% to $648.9 million, but narrowly beat analysts' average estimate of $645.33 million, according to three analysts polled by Refinitiv.
The drugmaker now expects 2019 adjusted earnings per share to be in the range $5.75 to $5.85, up from the prior range of $5.67 to $5.77.
Net income rose to $1.25 billion, or $1.37 per share, in the quarter ended Sept. 30, from $1.15 billion, or $1.12 per share, a year earlier.
Excluding items, Lilly earned $1.48 per share. Analysts on average had expected a profit of $1.41 per share, according to IBES data from Refinitiv.
Revenue rose 3.2% to $5.48 billion in the quarter but missed Wall Street expectation of $5.50 billion, largely due to flat overall sales in the United States.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.